Table of Contents
Thrombosis
Volume 2011 (2011), Article ID 794240, 9 pages
http://dx.doi.org/10.1155/2011/794240
Clinical Study

The CYTO-PV: A Large-Scale Trial Testing the Intensity of CYTOreductive Therapy to Prevent Cardiovascular Events in Patients with Polycythemia Vera

1CYTO-PV Coordinating Center, Consorzio Mario Negri Sud, Via Nazionale, 66030 Santa Maria Imbaro, Italy
2Unit of Hematology, Ospedali Riuniti di Bergamo, Bergamo, Italy
3Division of Hematology, University of Bari, Bari, Italy
4Consorzio Mario Negri Sud, Santa Maria Imbaro, Italy

Received 7 December 2010; Accepted 22 February 2011

Academic Editor: Paolo Simioni

Copyright © 2011 Roberto Marchioli et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. R. Landolfi, R. Marchioli, and C. Patrono, “Mechanisms of bleeding and thrombosis in myeloproliferative disorders,” Thrombosis and Haemostasis, vol. 78, no. 1, pp. 617–621, 1997. View at Google Scholar · View at Scopus
  2. R. Landolfi, L. Di Gennaro, and A. Falanga, “Thrombosis in myeloproliferative disorders: pathogenetic facts and speculation,” Leukemia, vol. 22, no. 11, pp. 2020–2028, 2008. View at Publisher · View at Google Scholar · View at Scopus
  3. J. L. Spivak, “Polycythemia vera: myths, mechanisms, and management,” Blood, vol. 100, no. 13, pp. 4272–4290, 2002. View at Publisher · View at Google Scholar · View at Scopus
  4. J. L. Spivak and R. T. Silver, “The revised world health organization diagnostic criteria for polycythemia vera, essential thrombocytosis, and primary myelofibrosis: an alternative proposal,” Blood, vol. 112, no. 2, pp. 231–239, 2008. View at Publisher · View at Google Scholar · View at Scopus
  5. T. C. Pearson and G. Wetherley-Mein, “Vascular occlusive episodes and venous haematocrit in primary proliferative polycythaemia,” Lancet, vol. 2, no. 8102, pp. 1219–1222, 1978. View at Google Scholar · View at Scopus
  6. D. J. Thomas, J. Marshall, R. W. Russell et al., “Effect of haematocrit on cerebral blood-flow in man,” Lancet, vol. 2, no. 8045, pp. 941–943, 1977. View at Google Scholar · View at Scopus
  7. G. Finazzi and T. Barbui, “How I treat patients with polycythemia vera,” Blood, vol. 109, no. 12, pp. 5104–5111, 2007. View at Publisher · View at Google Scholar · View at Scopus
  8. P. D. Berk, J. D. Goldberg, P. B. Donovan, S. M. Fruchtman, N. I. Berlin, and L. R. Wasserman, “Therapeutic recommendations in polycythemia vera based on Polycythemia Vera Study Group protocols,” Seminars in Hematology, vol. 23, no. 2, pp. 132–143, 1986. View at Google Scholar · View at Scopus
  9. T. Barbui, A. Carobbio, A. Rambaldi, and G. Finazzi, “Perspectives on thrombosis in essential thrombocythemia and polycythemia vera: is leukocytosis a causative factor?” Blood, vol. 114, no. 4, pp. 759–763, 2009. View at Publisher · View at Google Scholar · View at Scopus
  10. G. Finazzi and T. Barbui, “Expertise-based management in essential thrombocythemia and polycythemia vera,” Cancer Journal, vol. 13, no. 6, pp. 372–376, 2007. View at Publisher · View at Google Scholar · View at Scopus
  11. M. F. McMullin, D. Bareford, P. Campbell et al., “Guidelines for the diagnosis, investigation and management of polycythaemia/erythrocytosis,” British Journal of Haematology, vol. 130, no. 2, pp. 174–195, 2005. View at Publisher · View at Google Scholar
  12. P. D. Berk, J. D. Goldberg, P. B. Donovan, S. M. Fruchtman, N. I. Berlin, and L. R. Wasserman, “Therapeutic recommendations in polycythemia vera based on Polycythemia Vera Study Group protocols,” Seminars in Hematology, vol. 23, no. 2, pp. 132–143, 1986. View at Google Scholar · View at Scopus
  13. M. Di Nisio, T. Barbui, L. Di Gennaro et al., “The haematocrit and platelet target in polycythemia vera,” British Journal of Haematology, vol. 136, no. 2, pp. 249–259, 2007. View at Publisher · View at Google Scholar
  14. M. B. Streiff, B. Smith, and J. L. Spivak, “The diagnosis and management of polycythemia vera in the era since the Polycythemia Vera Study Group: a survey of american society of hematology members' practice patterns,” Blood, vol. 99, no. 4, pp. 1144–1149, 2002. View at Publisher · View at Google Scholar · View at Scopus
  15. A. Tefferi and J. L. Spivak, “Polycythemia vera: scientific advances and current practice,” Seminars in Hematology, vol. 42, no. 4, pp. 206–220, 2005. View at Publisher · View at Google Scholar · View at Scopus
  16. R. Landolfi and L. Di Gennaro, “Prevention of thrombosis in polycythemia vera and essential thrombocythemia,” Haematologica, vol. 93, no. 3, pp. 331–335, 2008. View at Publisher · View at Google Scholar · View at Scopus
  17. A. Tefferi, T. L. Lasho, S. M. Schwager et al., “The clinical phenotype of wild-type, heterozygous, and homozygous JAK2 in polycythemia vera,” Cancer, vol. 106, no. 3, pp. 631–635, 2006. View at Publisher · View at Google Scholar · View at Scopus
  18. A. M. Vannucchi, E. Antonioli, P. Guglielmelli et al., “Prospective identification of high-risk polycythemia vera patients based on JAK2V617F allele burden,” Leukemia, vol. 21, no. 9, pp. 1952–1959, 2007. View at Publisher · View at Google Scholar
  19. H. C. Hemker, R. Al Dieri, E. De Smedt, and S. Béguin, “Thrombin generation, a function test of the haemostatic-thrombotic system,” Thrombosis and Haemostasis, vol. 96, no. 5, pp. 553–561, 2006. View at Publisher · View at Google Scholar · View at Scopus
  20. Y. Dargaud, M. C. Trzeciak, J. C. Bordet, J. Ninet, and C. Negrier, “Use of calibrated automated thrombinography ± thrombomodulin to recognise the prothrombotic phenotype,” Thrombosis and Haemostasis, vol. 96, no. 5, pp. 562–567, 2006. View at Publisher · View at Google Scholar · View at Scopus
  21. A. J. Ten Cate-Hoek, A. W. J. H. Dielis, H. M. H. Spronk et al., “Thrombin generation in patients after acute deep-vein thrombosis,” Thrombosis and Haemostasis, vol. 100, no. 2, pp. 240–245, 2008. View at Publisher · View at Google Scholar · View at Scopus
  22. M. Besser, C. Baglin, R. Luddington, A. Van Hylckama Vlieg, and T. Baglin, “High rate of unprovoked recurrent venous thrombosis is associated with high thrombin-generating potential in a prospective cohort study,” Journal of Thrombosis and Haemostasis, vol. 6, no. 10, pp. 1720–1725, 2008. View at Publisher · View at Google Scholar · View at Scopus
  23. R. Marchioli, R. Landolfi, T. Barbui, and G. Tognoni, “Feasibility of randomised clinical trials in rare diseases: the case of polycythemia vera,” Leukemia and Lymphoma, vol. 22, no. 1, supplement, pp. 121–127, 1996. View at Google Scholar · View at Scopus